Although HDAC inhibitors have neuroprotective properties in animal models for various neurological diseases including Alzheimer's disease and ischaemic stroke 4, 5, current HDAC inhibitors are mostly nonselective, and different HDACs serve very distinct functions. This evidence concerns the gene HDAC9 and early-onset autosomal dominant Alzheimer disease.